

**CERTIFICATE UNDER 37 CFR 3.73(b)**

First Applicant: Meilin LIU

Serial No.: 10/593,804

Application Date: 13 March 2007

US Nat'l Entry Date:

Entitled: HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY

ImClone Systems Incorporated, a Delaware Corporation

(Name of Assignee)

(Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above.

☒ The assignment was recorded in the Patent and Trademark Office at Reel 019928, Frame 0161.

☐ The assignment is being submitted separately for recordation; a copy of this assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

March 27, 2009  
Date

  
Gregory A. Cox  
Patent Counsel

**Delegation of Authority Concerning**  
**Certain Patent Matters**

Pursuant to the authority granted to me by Gino Santini, President, ImClone Systems Corp., in a document dated February 3, 2009 (a copy which is attached as Appendix A), I delegate to each of the following persons:

Arvie J. Anderson	45,263	Paul J. Koivuniemi	31,533
Lynn D. Apelgren	45,341	Robert E. Lee	27,919
Robert A. Armitage	27,417	James P. Leeds	35,241
Brian P. Barrett	39,597	Nelsen L. Lentz	38,537
Gary M. Birch	48,881	Alejandro Martinez	58,163
Steven P. Caltrider	36,467	Elizabeth A. McGraw	44,646
Paul R. Cantrell	36,470	James B. Myers	42,021
John A. Cleveland, Jr.	50,697	Douglas K. Norman	33,267
Charles E. Cohen	34,565	Arleen Palmberg	40,422
Tonya L. Combs	57,909	Thomas G. Plant	35,784
Donald L. Corneglio	30,741	Edward J. Prein	37,212
Gregory A. Cox	47,504	Robert L. Sharp	45,609
Paula K. Davis	47,517	Mark J. Stewart	43,936
John C. Demeter	30,167	Robert D. Titus	40,206
Manisha A. Desai	43,585	R. Craig Tucker	45,165
Ted Ebersole	51,641	Tina M. Tucker	47,145
Paul J. Gaylo	36,808	MaCharri Vorndran-Jones	36,711
Caren D. Geppert	54,117	Gilbert T. Voy	43,972
Francis O. Ginah	44,712	Lawrence T. Welch	29,487
Amy E. Hamilton	33,894	Alexander Wilson	45,782
Averie Hason	57,722	Mark A. Winter	53,782
Danica Hostettler	51,820	MaryAnn Wiskerchen	45,511
Thomas E. Jackson	33,064	Dan L. Wood	48,613
Sanjay M. Jivraj	61,806	Nicole Woods	56,579
Gerald P. Keleher	43,707	Congping Xie	57,817
James J. Kelley	41,888		

all of whom are registered to practice before the United States Patent and Trademark Office and are employees of Eli Lilly and Company, the authority to approve and execute for and on behalf of the Company, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of contests, and abandonments of the invention;


(iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of the Company;

(v) the filing of statutory disclaimers;

(vi) the institution, prosecution, and termination of appellate proceedings; and

(vii) the granting and the revocation of powers of attorney in connection with any of the foregoing, except there shall be no authority to revoke any power of attorney held by the Vice President and General Patent Counsel, Lilly Research Laboratories (a division of the Company).

Dated: 6 February 2009

  
\_\_\_\_\_  
Douglas K. Norman  
Vice President and General Patent Counsel


**Delegation of Authority Concerning  
Certain Patent Matters**

On behalf of ImClone Systems Corporation (ImClone), a Delaware corporation with a principal place of business at 180 Varick Street, New York City, New York, a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis Indiana 46285, I delegate to Douglas K. Norman, Vice President and General Patent Counsel of Eli Lilly and Company; Amy E. Hamilton, Deputy General Patent Counsel of Eli Lilly and Company; and James J. Kelley, Assistant General Patent Counsel of Eli Lilly and Company:

Authority to approve and execute for and on behalf of ImClone, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of the contents, and abandonments of the invention;
- (iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of Eli Lilly and Company;
- (v) the filing of statutory disclaimers;
- (vi) the institution, prosecution, and termination of appellate proceedings; and
- (vii) the granting and the revocation of powers of attorney in connection with any of the foregoing.

Dated: 2/3/09

  
\_\_\_\_\_  
Gino Santini  
President, ImClone Systems Corp.